FIELD: medicine, pharmaceutics.
SUBSTANCE: presented group of inventions refers to a combined vaccine, using it and a method for preparing it. The characterised vaccine involves an antigen mixture for the protection against such diseases, as diphtheria (D), tetanus (T), acellular pertussis (aP) and infections caused by Haemophilus influenzae (Hib b) and polioviruses (IPV). The Hib b antigen in the characterised vaccine is conjugated with a carrier protein specified in a group consisting of tetanus anatoxin, diphtheria anatoxin, CRM 197 and Neisseria meningitides outer membrane protein, or any equivalent thereof, wherein the IPV antigens represent Salk strains specified in a group consisting of Mahoney type 1, MEF type 2 and Saukett type 3, or Sabin strains specified in the group of Sabin 1 or 2, and wherein aP includes at least one or more antigens from the group consisting of pertussis anatoxin (PT), filamentous haemagglutinin (FHA), pertactin (P69 or PRN) and fimbrial proteins (FIM 1, 2 and 3). All the vaccine components are presented in the liquid state and stable, while Hib b is found in an amount of 10 mcg per 0.5 ml of the vaccine.
EFFECT: presented inventions provide the protection against various infections.
10 cl, 3 tbl, 3 ex
